- published: 11 Sep 2014
- views: 2400
Create your page here
-
remove the playlistCelgene
- remove the playlistCelgene
back to playlist
Robert J. Hugin (MBA '85), a member of the Darden School Foundation Board of Trustees, and the Chairman and Chief Executive Officer of Celgene Corporation spoke as part of the 2014-15 Darden Leadership Speaker Series - “Leaders that inspire innovation, collaboration and growth”.
FierceBiotech, a biotech industry newsletter, called him the man with the big biopharma growth plan; stated that “…chief executive and chairman of Celgene [Bob Hugin] is undeniably influential at his company and around the industry”; and, also named him as #10 on their 2013 25 most influential people in biopharma today list. His visit was co-sponsored by the Darden Health Care Club.
Recorded 10 September 2014. For information about Mr. Hugin and Celgene Corporation, visit http://www.celgene.com.
VIDEO FINANCIAL REPORTING
Why invest in is the first financial video platform where you can easily search through thousands of videos describing global securities.
About The Video:
We believe that complex financial data could become more approachable using friendly motion-graphic representation combined with an accurate selection of financial data. To guarantee the most effective information prospective we drew inspiration from Benjamin Graham’s book: “The Intelligent Investor”, a pillar of financial philosophy.
For this project any kind of suggestion or critic will be helpful in order to develop and provide the best service as we can. Please visit our site www.whyinvestin.com and leave a massage to us.
Thank you and hope you'll enjoy.
IMPORTANT INFORMATION - DISCLAIMER
THIS VIDEO IS FOR INFORMATION PURPOSES ONLY AND SHOULD NOT BE RELIED UPON AS INVESTMENT ADVICE. This video has been prepared by Whyinvestin (together with its affiliates, “Whyinvestin”) and is not intended to be taken by, and should not be taken by, any individual recipient as investment advice, a recommendation to buy, hold or sell any security, or an offer to sell or a solicitation of offers to purchase any security.
PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. The performance of the companies discussed on this video is not necessarily indicative of the future performances.
Investors should consider the content of this video in conjunction with investment reports, financial statements and other disclosures regarding the valuations and performance of the specific companies discussed herein.
DO NOT RELY ON ANY OPINIONS, PREDICTIONS OR FORWARD-LOOKING STATEMENTS CONTAINED HEREIN. Certain of the information contained in this video constitutes “forward-looking statements” that are inherently unreliable and actual events or results may differ materially from those reflected or contemplated herein. None of Whyinvestin or any of its representatives makes any assurance as to the accuracy of those predictions or forward-looking statements. Whyinvestin expressly disclaims any obligation or undertaking to update or revise any such forward-looking statements.
EXTERNAL SOURCES. Certain information contained herein has been obtained from third-party sources. Although Whyinvestin believes such sources to be reliable, we make no representation as to its accuracy or completeness.
FINANCIAL DATA Companies Data is publicly available. Data and calculations have been sourced from our Team, “Sharadar”, (http://www.sharadar.com), Rufus Pollock and from the Open Knowledge Foundation. All data is licensed under the Open Data Commons Public Domain Dedication and License.
Whyinvestin does not verify any data and disclaims any obligation to do so. Whyinvestin, its data or content providers, the financial exchanges and each of their affiliates and business partners (A) expressly disclaim the accuracy, adequacy, or completeness of any data and (B) shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon. Neither Whyinvestin nor any of our information providers will be liable for any damages relating to your use of the information provided herein.
Please consult your broker or financial representative to verify pricing before executing any trade. Whyinvestin cannot guarantee the accuracy of the exchange rates used in the videos. You should confirm current rates before making any transactions that could be affected by changes in the exchange rates.
You agree not to copy, modify, reformat, download, store, reproduce, reprocess, transmit or redistribute any data or information found herein or use any such data or information in a commercial enterprise without obtaining prior written consent. Please consult your broker or financial representative to verify pricing before executing any trade.
COPYRIGHT “FAIR USE” Whyinvestin doesn’t own any logo different from the whyinvestin’ s logo contained in the video.
The owner of the logos is the subject of the video itself (the company); and all the logos are not authorized by, sponsored by, or associated with the trademark owner .
Whyinvestin uses exclusive rights held by the copyright owner for Educational purposes and for commentary and criticism as part of a news report or published article.
If you are a company, subject of the video and for any reason want to get in contact with Whyinvestin please email:
company@whyinvestin.com
- published: 16 Feb 2015
- views: 303
What's up guys! I've had the most amazing few days visiting Celgene and learning about the future of cellular biology and how it will play into food manufacturing.
These guys are the real deal. They're asking the questions nobody else is asking. But more importantly, they're answering questions no one else can answer. It is an incredible honor to be part of a brain trust of this caliber. Just being around this kind of high-level thinking is inspiring. Remember, you're the average of the 5 people you spend the most time with, so choose wisely.
Check out our website: www.insidequest.com
Follow me on Instagram: https://www.instagram.com/tombilyeu/
- published: 16 Nov 2015
- views: 586
Entrevista completa de Redacción Médica a Marta Moreno, Senior Director, Government Affairs & Market Access de Celgene.
- published: 07 Nov 2015
- views: 82
From the 15th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York on February 11th, 2013.
Robert Hugin
Chairman and Chief Executive Officer, Celgene Corporation
Mr. Hugin serves as Chairman and Chief Executive Officer of Celgene Corporation, a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for unmet medical needs in cancer and immune-inflammatory disease.
He joined Celgene in June 1999 and has been a Director of Celgene since December 2001. Mr. Hugin also serves as a Director of The Medicines Company, Atlantic Health System, Inc. and of Family Promise, a national non-profit network assisting homeless families. He serves as Chairman-Elect of The Pharmaceutical Research and Manufacturers of America and is a member of the Board of Trustees of The Darden Foundation, University of Virginia. He also serves on the Board of Trustees of Princeton University as well as a founding Board member of Choose NJ.
Prior to joining Celgene, Mr. Hugin was a Managing Director with J.P. Morgan & Co. Inc. Mr. Hugin received an AB degree from Princeton University in 1976 and an MBA from the University of Virginia in 1985 and served as a United States Marine Corps infantry officer during the intervening period. Bob and his wife Kathy have three children and live in Summit, New Jersey.
- published: 27 Feb 2013
- views: 1757
Oct. 28 (Bloomberg) -- Robert Hugin, chief executive officer of Celgene Corp., talks about possible generic competition for Celgene's best-selling Revlimid cancer pill.
Hugin also discusses Celgene's drug pipeline and the acquisition of Abraxis BioScience Inc. He talks with Carol Massar and Matt Miller on Bloomberg Television's "Street Smart." (Source: Bloomberg)
- published: 23 Mar 2012
- views: 780
The best defense is a good offense. A closer look at Celgene and Juno’s 10-year developing and marketing agreement.
This podcast was recorded on Jan 6, 2016.
Imagine owning Amazon.com (up over an insane 4,000% since 2001) when Internet sales rendered big-box retailers obsolete... Now an industry 99% of us use daily is set to implode... And 3 established companies are positioned to take advantage. Click http://bit.ly/1zQXjzy for a stunning presentation.
------------------------------------------------------------------------
Subscribe to The Motley Fool's YouTube Channel:
http://www.youtube.com/TheMotleyFool
Or, follow our Google+ page:
https://plus.google.com/+MotleyFool/posts
Inside The Motley Fool: Check out our Culture Blog!
http://culture.fool.com
Join our Facebook community:
https://www.facebook.com/themotleyfool
Follow The Motley Fool on Twitter:
https://twitter.com/themotleyfool
- published: 08 Jan 2016
- views: 203
Jim Cramer talks growth in the biotech space with Mad Money research director Nicole Urken
- published: 27 Mar 2013
- views: 1199
Emission du 18.07.2013
Il n'est pas tombé dedans quand il était petit! Nair a découvert l'informatique chez son cousin, mais de là à en faire son métier! Et pourtant, il s'est lancé dans le domaine, sans stages préalables et ça a été une révélation. Comble de chance, il a décroché sa place dans la prestigieuse entreprise internationale Celgene à Boudry.
A voir aussi sur :
http://monjobetmoi.ch
http://www.canalalpha.ch/emissions/monjobetmoi/
- published: 02 Feb 2016
- views: 16
Celgene Corporation (NASDAQ: CELG) is an American biotechnology company that manufacturers of drug therapies for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major products are Thalomid (thalidomide), which is approved for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum ("ENL"), as well as in combination with dexamethasone for patients with newly diagnosed multiple myeloma, and Revlimid (lenalidomide), for which the company has received FDA and EMEA approval in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Both Thalomid and Revlimid are sold through proprietary risk-management distribution programs to ensure safe and appropriate use of these pharmaceuticals. Vidaza is approved for the treatment of patients with MDS. Celgene also receives royalties from Novartis Pharma AG on sales of the entire Ritalin family of drugs, which are widely used to treat Attention Deficit Hyperactivity Disorder (ADHD).
This page contains text from Wikipedia, the Free Encyclopedia -
http://en.wikipedia.org/wiki/Celgene
This article is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License, which means that you can copy and modify it as long as the entire work (including additions) remains under this license.
This article is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License, which means that you can copy and modify it as long as the entire work (including additions) remains under this license.
- Loading...
-
69:53Robert J. Hugin, Chairman & CEO of Celgene Corporation
Robert J. Hugin, Chairman & CEO of Celgene CorporationRobert J. Hugin, Chairman & CEO of Celgene Corporation
Robert J. Hugin (MBA '85), a member of the Darden School Foundation Board of Trustees, and the Chairman and Chief Executive Officer of Celgene Corporation spoke as part of the 2014-15 Darden Leadership Speaker Series - “Leaders that inspire innovation, collaboration and growth”. FierceBiotech, a biotech industry newsletter, called him the man with the big biopharma growth plan; stated that “…chief executive and chairman of Celgene [Bob Hugin] is undeniably influential at his company and around the industry”; and, also named him as #10 on their 2013 25 most influential people in biopharma today list. His visit was co-sponsored by the Darden Health Care Club. Recorded 10 September 2014. For information about Mr. Hugin and Celgene Corporation, visit http://www.celgene.com. -
2:09Celgene Corp - Why Invest in
Celgene Corp - Why Invest inCelgene Corp - Why Invest in
VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global securities. About The Video: We believe that complex financial data could become more approachable using friendly motion-graphic representation combined with an accurate selection of financial data. To guarantee the most effective information prospective we drew inspiration from Benjamin Graham’s book: “The Intelligent Investor”, a pillar of financial philosophy. For this project any kind of suggestion or critic will be helpful in order to develop and provide the best service as we can. Please visit our site www.whyinvestin.com and leave a massage to us. Thank you and hope you'll enjoy. IMPORTANT INFORMATION - DISCLAIMER THIS VIDEO IS FOR INFORMATION PURPOSES ONLY AND SHOULD NOT BE RELIED UPON AS INVESTMENT ADVICE. This video has been prepared by Whyinvestin (together with its affiliates, “Whyinvestin”) and is not intended to be taken by, and should not be taken by, any individual recipient as investment advice, a recommendation to buy, hold or sell any security, or an offer to sell or a solicitation of offers to purchase any security. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. The performance of the companies discussed on this video is not necessarily indicative of the future performances. Investors should consider the content of this video in conjunction with investment reports, financial statements and other disclosures regarding the valuations and performance of the specific companies discussed herein. DO NOT RELY ON ANY OPINIONS, PREDICTIONS OR FORWARD-LOOKING STATEMENTS CONTAINED HEREIN. Certain of the information contained in this video constitutes “forward-looking statements” that are inherently unreliable and actual events or results may differ materially from those reflected or contemplated herein. None of Whyinvestin or any of its representatives makes any assurance as to the accuracy of those predictions or forward-looking statements. Whyinvestin expressly disclaims any obligation or undertaking to update or revise any such forward-looking statements. EXTERNAL SOURCES. Certain information contained herein has been obtained from third-party sources. Although Whyinvestin believes such sources to be reliable, we make no representation as to its accuracy or completeness. FINANCIAL DATA Companies Data is publicly available. Data and calculations have been sourced from our Team, “Sharadar”, (http://www.sharadar.com), Rufus Pollock and from the Open Knowledge Foundation. All data is licensed under the Open Data Commons Public Domain Dedication and License. Whyinvestin does not verify any data and disclaims any obligation to do so. Whyinvestin, its data or content providers, the financial exchanges and each of their affiliates and business partners (A) expressly disclaim the accuracy, adequacy, or completeness of any data and (B) shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon. Neither Whyinvestin nor any of our information providers will be liable for any damages relating to your use of the information provided herein. Please consult your broker or financial representative to verify pricing before executing any trade. Whyinvestin cannot guarantee the accuracy of the exchange rates used in the videos. You should confirm current rates before making any transactions that could be affected by changes in the exchange rates. You agree not to copy, modify, reformat, download, store, reproduce, reprocess, transmit or redistribute any data or information found herein or use any such data or information in a commercial enterprise without obtaining prior written consent. Please consult your broker or financial representative to verify pricing before executing any trade. COPYRIGHT “FAIR USE” Whyinvestin doesn’t own any logo different from the whyinvestin’ s logo contained in the video. The owner of the logos is the subject of the video itself (the company); and all the logos are not authorized by, sponsored by, or associated with the trademark owner . Whyinvestin uses exclusive rights held by the copyright owner for Educational purposes and for commentary and criticism as part of a news report or published article. If you are a company, subject of the video and for any reason want to get in contact with Whyinvestin please email: company@whyinvestin.com -
3:42Visiting Celgene
Visiting CelgeneVisiting Celgene
What's up guys! I've had the most amazing few days visiting Celgene and learning about the future of cellular biology and how it will play into food manufacturing. These guys are the real deal. They're asking the questions nobody else is asking. But more importantly, they're answering questions no one else can answer. It is an incredible honor to be part of a brain trust of this caliber. Just being around this kind of high-level thinking is inspiring. Remember, you're the average of the 5 people you spend the most time with, so choose wisely. Check out our website: www.insidequest.com Follow me on Instagram: https://www.instagram.com/tombilyeu/ -
17:28Entrevista a Marta Moreno, de Celgene
Entrevista a Marta Moreno, de CelgeneEntrevista a Marta Moreno, de Celgene
Entrevista completa de Redacción Médica a Marta Moreno, Senior Director, Government Affairs & Market Access de Celgene. -
49:06Fireside Chat With Robert Hugin, Chairman and Chief Executive Officer, Celgene Corporation
Fireside Chat With Robert Hugin, Chairman and Chief Executive Officer, Celgene CorporationFireside Chat With Robert Hugin, Chairman and Chief Executive Officer, Celgene Corporation
From the 15th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York on February 11th, 2013. Robert Hugin Chairman and Chief Executive Officer, Celgene Corporation Mr. Hugin serves as Chairman and Chief Executive Officer of Celgene Corporation, a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for unmet medical needs in cancer and immune-inflammatory disease. He joined Celgene in June 1999 and has been a Director of Celgene since December 2001. Mr. Hugin also serves as a Director of The Medicines Company, Atlantic Health System, Inc. and of Family Promise, a national non-profit network assisting homeless families. He serves as Chairman-Elect of The Pharmaceutical Research and Manufacturers of America and is a member of the Board of Trustees of The Darden Foundation, University of Virginia. He also serves on the Board of Trustees of Princeton University as well as a founding Board member of Choose NJ. Prior to joining Celgene, Mr. Hugin was a Managing Director with J.P. Morgan & Co. Inc. Mr. Hugin received an AB degree from Princeton University in 1976 and an MBA from the University of Virginia in 1985 and served as a United States Marine Corps infantry officer during the intervening period. Bob and his wife Kathy have three children and live in Summit, New Jersey. -
5:00Hugin Sees Celgene Revlimid Patents Holding Until 2027
Hugin Sees Celgene Revlimid Patents Holding Until 2027Hugin Sees Celgene Revlimid Patents Holding Until 2027
Oct. 28 (Bloomberg) -- Robert Hugin, chief executive officer of Celgene Corp., talks about possible generic competition for Celgene's best-selling Revlimid cancer pill. Hugin also discusses Celgene's drug pipeline and the acquisition of Abraxis BioScience Inc. He talks with Carol Massar and Matt Miller on Bloomberg Television's "Street Smart." (Source: Bloomberg) -
6:01Digging into Deals: Why Celgene Joined Up With Juno Therapeutics In 2015
Digging into Deals: Why Celgene Joined Up With Juno Therapeutics In 2015Digging into Deals: Why Celgene Joined Up With Juno Therapeutics In 2015
The best defense is a good offense. A closer look at Celgene and Juno’s 10-year developing and marketing agreement. This podcast was recorded on Jan 6, 2016. Imagine owning Amazon.com (up over an insane 4,000% since 2001) when Internet sales rendered big-box retailers obsolete... Now an industry 99% of us use daily is set to implode... And 3 established companies are positioned to take advantage. Click http://bit.ly/1zQXjzy for a stunning presentation. ------------------------------------------------------------------------ Subscribe to The Motley Fool's YouTube Channel: http://www.youtube.com/TheMotleyFool Or, follow our Google+ page: https://plus.google.com/+MotleyFool/posts Inside The Motley Fool: Check out our Culture Blog! http://culture.fool.com Join our Facebook community: https://www.facebook.com/themotleyfool Follow The Motley Fool on Twitter: https://twitter.com/themotleyfool -
2:20Next Big Thing in Biotech: Celgene
Next Big Thing in Biotech: CelgeneNext Big Thing in Biotech: Celgene
Next Big Thing in Biotech: Celgene -
2:16Cramer: Why Celgene Makes Sense
Cramer: Why Celgene Makes Sense -
3:08Mad Money Uncovered: Biogen and Celgene, Biotech innovators
Mad Money Uncovered: Biogen and Celgene, Biotech innovatorsMad Money Uncovered: Biogen and Celgene, Biotech innovators
Jim Cramer talks growth in the biotech space with Mad Money research director Nicole Urken -
7:47(CELG) Celgene Corporation
(CELG) Celgene Corporation -
3:01Nair apprenti informaticien chez Celgene
Nair apprenti informaticien chez CelgeneNair apprenti informaticien chez Celgene
Emission du 18.07.2013 Il n'est pas tombé dedans quand il était petit! Nair a découvert l'informatique chez son cousin, mais de là à en faire son métier! Et pourtant, il s'est lancé dans le domaine, sans stages préalables et ça a été une révélation. Comble de chance, il a décroché sa place dans la prestigieuse entreprise internationale Celgene à Boudry. A voir aussi sur : http://monjobetmoi.ch http://www.canalalpha.ch/emissions/monjobetmoi/
- Adobe Systems
- Akamai Technologies
- Altera
- Amazon.com
- Amgen
- Apollo Group
- Apple Inc.
- Applied Materials
- Asset
- Autodesk
- Avago Technologies
- Azacitidine
- Baidu
- Bed Bath & Beyond
- Biogen Idec
- Biotechnology
- BMC Software
- Broadcom
- CA Technologies
- Celanese
- Celgene
- Cerner
- Chairman
- Check Point
- Cisco Systems
- Citrix Systems
- Comcast
- Cord blood bank
- Costco
- Ctrip
- Dell
- Dentsply
- Dexamethasone
- DirecTV
- Dollar Tree
- EBay
- Electronic Arts
- Equity (finance)
- Expedia, Inc.
- Express Scripts
- F5 Networks
- Fastenal
- Fiserv
- Flextronics
- Fossil, Inc.
- Garmin
- Gilead Sciences
- GlaxoSmithKline
- Henry Schein
- Infosys
- Intel Corporation
- Intuit
- Intuitive Surgical
- KLA Tencor
- Lam Research
- Lenalidomide
- Liberty Interactive
- Life Technologies
- Linear Technology
- Mattel
- Melphalan
- Microchip Technology
- Micron Technology
- Microsoft
- Monster Beverage
- Multiple myeloma
- Mylan
- NASDAQ
- NASDAQ-100
- Net income
- NetApp
- Netflix
- News Corporation
- Novartis
- Nvidia
- O'Reilly Auto Parts
- Oracle Corporation
- Paccar
- Paychex
- Perrigo
- Portal Companies
- Priceline.com
- Public company
- Qualcomm
- Randgold Resources
- Research In Motion
- Ross Stores
- S&P; 500
- SanDisk
- Seagate Technology
- Sigma-Aldrich
- Sirius XM Radio
- Staples Inc.
- Starbucks
- Stericycle
- Summit, New Jersey
- Symantec
- Template NASDAQ-100
- Texas Instruments
- Thalidomide
- Ticker symbol
- United States
- United States dollar
- Verisign
- Virgin Media
- Vodafone
- Warner Chilcott
- Whole Foods Market
- Wynn Resorts
- Xilinx
- Yahoo!
-
Robert J. Hugin, Chairman & CEO of Celgene Corporation
Robert J. Hugin (MBA '85), a member of the Darden School Foundation Board of Trustees, and the Chairman and Chief Executive Officer of Celgene Corporation spoke as part of the 2014-15 Darden Leadership Speaker Series - “Leaders that inspire innovation, collaboration and growth”. FierceBiotech, a biotech industry newsletter, called him the man with the big biopharma growth plan; stated that “…chief executive and chairman of Celgene [Bob Hugin] is undeniably influential at his company and around the industry”; and, also named him as #10 on their 2013 25 most influential people in biopharma today list. His visit was co-sponsored by the Darden Health Care Club. Recorded 10 September 2014. For information about Mr. Hugin and Celgene Corporation, visit http://www.celgene.com. -
Celgene Corp - Why Invest in
VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global securities. About The Video: We believe that complex financial data could become more approachable using friendly motion-graphic representation combined with an accurate selection of financial data. To guarantee the most effective information prospective we drew inspiration from Benjamin Graham’s book: “The Intelligent Investor”, a pillar of financial philosophy. For this project any kind of suggestion or critic will be helpful in order to develop and provide the best service as we can. Please visit our site www.whyinvestin.com and leave a massage to us. Thank you and hope you'll enjoy. IMPORTANT INFORMATION - DISCLAIMER THIS VIDEO IS... -
Visiting Celgene
What's up guys! I've had the most amazing few days visiting Celgene and learning about the future of cellular biology and how it will play into food manufacturing. These guys are the real deal. They're asking the questions nobody else is asking. But more importantly, they're answering questions no one else can answer. It is an incredible honor to be part of a brain trust of this caliber. Just being around this kind of high-level thinking is inspiring. Remember, you're the average of the 5 people you spend the most time with, so choose wisely. Check out our website: www.insidequest.com Follow me on Instagram: https://www.instagram.com/tombilyeu/ -
Entrevista a Marta Moreno, de Celgene
Entrevista completa de Redacción Médica a Marta Moreno, Senior Director, Government Affairs & Market Access de Celgene. -
Fireside Chat With Robert Hugin, Chairman and Chief Executive Officer, Celgene Corporation
From the 15th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York on February 11th, 2013. Robert Hugin Chairman and Chief Executive Officer, Celgene Corporation Mr. Hugin serves as Chairman and Chief Executive Officer of Celgene Corporation, a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for unmet medical needs in cancer and immune-inflammatory disease. He joined Celgene in June 1999 and has been a Director of Celgene since December 2001. Mr. Hugin also serves as a Director of The Medicines Company, Atlantic Health System, Inc. and of Family Promise, a national non-profit network assisting homeless families. He serves as Chairman-Elect of The Pharmaceutical Research and Manufacturers of America an... -
Hugin Sees Celgene Revlimid Patents Holding Until 2027
Oct. 28 (Bloomberg) -- Robert Hugin, chief executive officer of Celgene Corp., talks about possible generic competition for Celgene's best-selling Revlimid cancer pill. Hugin also discusses Celgene's drug pipeline and the acquisition of Abraxis BioScience Inc. He talks with Carol Massar and Matt Miller on Bloomberg Television's "Street Smart." (Source: Bloomberg) -
Digging into Deals: Why Celgene Joined Up With Juno Therapeutics In 2015
The best defense is a good offense. A closer look at Celgene and Juno’s 10-year developing and marketing agreement. This podcast was recorded on Jan 6, 2016. Imagine owning Amazon.com (up over an insane 4,000% since 2001) when Internet sales rendered big-box retailers obsolete... Now an industry 99% of us use daily is set to implode... And 3 established companies are positioned to take advantage. Click http://bit.ly/1zQXjzy for a stunning presentation. ------------------------------------------------------------------------ Subscribe to The Motley Fool's YouTube Channel: http://www.youtube.com/TheMotleyFool Or, follow our Google+ page: https://plus.google.com/+MotleyFool/posts Inside The Motley Fool: Check out our Culture Blog! http://culture.fool.com Join our Facebook community: http... -
Next Big Thing in Biotech: Celgene
Next Big Thing in Biotech: Celgene -
-
Mad Money Uncovered: Biogen and Celgene, Biotech innovators
Jim Cramer talks growth in the biotech space with Mad Money research director Nicole Urken -
-
Nair apprenti informaticien chez Celgene
Emission du 18.07.2013 Il n'est pas tombé dedans quand il était petit! Nair a découvert l'informatique chez son cousin, mais de là à en faire son métier! Et pourtant, il s'est lancé dans le domaine, sans stages préalables et ça a été une révélation. Comble de chance, il a décroché sa place dans la prestigieuse entreprise internationale Celgene à Boudry. A voir aussi sur : http://monjobetmoi.ch http://www.canalalpha.ch/emissions/monjobetmoi/
Robert J. Hugin, Chairman & CEO of Celgene Corporation
- Order: Reorder
- Duration: 69:53
- Updated: 11 Sep 2014
- views: 2400
Robert J. Hugin (MBA '85), a member of the Darden School Foundation Board of Trustees, and the Chairman and Chief Executive Officer of Celgene Corporation spoke...
Robert J. Hugin (MBA '85), a member of the Darden School Foundation Board of Trustees, and the Chairman and Chief Executive Officer of Celgene Corporation spoke as part of the 2014-15 Darden Leadership Speaker Series - “Leaders that inspire innovation, collaboration and growth”.
FierceBiotech, a biotech industry newsletter, called him the man with the big biopharma growth plan; stated that “…chief executive and chairman of Celgene [Bob Hugin] is undeniably influential at his company and around the industry”; and, also named him as #10 on their 2013 25 most influential people in biopharma today list. His visit was co-sponsored by the Darden Health Care Club.
Recorded 10 September 2014. For information about Mr. Hugin and Celgene Corporation, visit http://www.celgene.com.
wn.com/Robert J. Hugin, Chairman Ceo Of Celgene Corporation
Robert J. Hugin (MBA '85), a member of the Darden School Foundation Board of Trustees, and the Chairman and Chief Executive Officer of Celgene Corporation spoke as part of the 2014-15 Darden Leadership Speaker Series - “Leaders that inspire innovation, collaboration and growth”.
FierceBiotech, a biotech industry newsletter, called him the man with the big biopharma growth plan; stated that “…chief executive and chairman of Celgene [Bob Hugin] is undeniably influential at his company and around the industry”; and, also named him as #10 on their 2013 25 most influential people in biopharma today list. His visit was co-sponsored by the Darden Health Care Club.
Recorded 10 September 2014. For information about Mr. Hugin and Celgene Corporation, visit http://www.celgene.com.
- published: 11 Sep 2014
- views: 2400
Celgene Corp - Why Invest in
- Order: Reorder
- Duration: 2:09
- Updated: 16 Feb 2015
- views: 303
VIDEO FINANCIAL REPORTING
Why invest in is the first financial video platform where you can easily search through thousands of videos describing global securit...
VIDEO FINANCIAL REPORTING
Why invest in is the first financial video platform where you can easily search through thousands of videos describing global securities.
About The Video:
We believe that complex financial data could become more approachable using friendly motion-graphic representation combined with an accurate selection of financial data. To guarantee the most effective information prospective we drew inspiration from Benjamin Graham’s book: “The Intelligent Investor”, a pillar of financial philosophy.
For this project any kind of suggestion or critic will be helpful in order to develop and provide the best service as we can. Please visit our site www.whyinvestin.com and leave a massage to us.
Thank you and hope you'll enjoy.
IMPORTANT INFORMATION - DISCLAIMER
THIS VIDEO IS FOR INFORMATION PURPOSES ONLY AND SHOULD NOT BE RELIED UPON AS INVESTMENT ADVICE. This video has been prepared by Whyinvestin (together with its affiliates, “Whyinvestin”) and is not intended to be taken by, and should not be taken by, any individual recipient as investment advice, a recommendation to buy, hold or sell any security, or an offer to sell or a solicitation of offers to purchase any security.
PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. The performance of the companies discussed on this video is not necessarily indicative of the future performances.
Investors should consider the content of this video in conjunction with investment reports, financial statements and other disclosures regarding the valuations and performance of the specific companies discussed herein.
DO NOT RELY ON ANY OPINIONS, PREDICTIONS OR FORWARD-LOOKING STATEMENTS CONTAINED HEREIN. Certain of the information contained in this video constitutes “forward-looking statements” that are inherently unreliable and actual events or results may differ materially from those reflected or contemplated herein. None of Whyinvestin or any of its representatives makes any assurance as to the accuracy of those predictions or forward-looking statements. Whyinvestin expressly disclaims any obligation or undertaking to update or revise any such forward-looking statements.
EXTERNAL SOURCES. Certain information contained herein has been obtained from third-party sources. Although Whyinvestin believes such sources to be reliable, we make no representation as to its accuracy or completeness.
FINANCIAL DATA Companies Data is publicly available. Data and calculations have been sourced from our Team, “Sharadar”, (http://www.sharadar.com), Rufus Pollock and from the Open Knowledge Foundation. All data is licensed under the Open Data Commons Public Domain Dedication and License.
Whyinvestin does not verify any data and disclaims any obligation to do so. Whyinvestin, its data or content providers, the financial exchanges and each of their affiliates and business partners (A) expressly disclaim the accuracy, adequacy, or completeness of any data and (B) shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon. Neither Whyinvestin nor any of our information providers will be liable for any damages relating to your use of the information provided herein.
Please consult your broker or financial representative to verify pricing before executing any trade. Whyinvestin cannot guarantee the accuracy of the exchange rates used in the videos. You should confirm current rates before making any transactions that could be affected by changes in the exchange rates.
You agree not to copy, modify, reformat, download, store, reproduce, reprocess, transmit or redistribute any data or information found herein or use any such data or information in a commercial enterprise without obtaining prior written consent. Please consult your broker or financial representative to verify pricing before executing any trade.
COPYRIGHT “FAIR USE” Whyinvestin doesn’t own any logo different from the whyinvestin’ s logo contained in the video.
The owner of the logos is the subject of the video itself (the company); and all the logos are not authorized by, sponsored by, or associated with the trademark owner .
Whyinvestin uses exclusive rights held by the copyright owner for Educational purposes and for commentary and criticism as part of a news report or published article.
If you are a company, subject of the video and for any reason want to get in contact with Whyinvestin please email:
company@whyinvestin.com
wn.com/Celgene Corp Why Invest In
VIDEO FINANCIAL REPORTING
Why invest in is the first financial video platform where you can easily search through thousands of videos describing global securities.
About The Video:
We believe that complex financial data could become more approachable using friendly motion-graphic representation combined with an accurate selection of financial data. To guarantee the most effective information prospective we drew inspiration from Benjamin Graham’s book: “The Intelligent Investor”, a pillar of financial philosophy.
For this project any kind of suggestion or critic will be helpful in order to develop and provide the best service as we can. Please visit our site www.whyinvestin.com and leave a massage to us.
Thank you and hope you'll enjoy.
IMPORTANT INFORMATION - DISCLAIMER
THIS VIDEO IS FOR INFORMATION PURPOSES ONLY AND SHOULD NOT BE RELIED UPON AS INVESTMENT ADVICE. This video has been prepared by Whyinvestin (together with its affiliates, “Whyinvestin”) and is not intended to be taken by, and should not be taken by, any individual recipient as investment advice, a recommendation to buy, hold or sell any security, or an offer to sell or a solicitation of offers to purchase any security.
PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. The performance of the companies discussed on this video is not necessarily indicative of the future performances.
Investors should consider the content of this video in conjunction with investment reports, financial statements and other disclosures regarding the valuations and performance of the specific companies discussed herein.
DO NOT RELY ON ANY OPINIONS, PREDICTIONS OR FORWARD-LOOKING STATEMENTS CONTAINED HEREIN. Certain of the information contained in this video constitutes “forward-looking statements” that are inherently unreliable and actual events or results may differ materially from those reflected or contemplated herein. None of Whyinvestin or any of its representatives makes any assurance as to the accuracy of those predictions or forward-looking statements. Whyinvestin expressly disclaims any obligation or undertaking to update or revise any such forward-looking statements.
EXTERNAL SOURCES. Certain information contained herein has been obtained from third-party sources. Although Whyinvestin believes such sources to be reliable, we make no representation as to its accuracy or completeness.
FINANCIAL DATA Companies Data is publicly available. Data and calculations have been sourced from our Team, “Sharadar”, (http://www.sharadar.com), Rufus Pollock and from the Open Knowledge Foundation. All data is licensed under the Open Data Commons Public Domain Dedication and License.
Whyinvestin does not verify any data and disclaims any obligation to do so. Whyinvestin, its data or content providers, the financial exchanges and each of their affiliates and business partners (A) expressly disclaim the accuracy, adequacy, or completeness of any data and (B) shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon. Neither Whyinvestin nor any of our information providers will be liable for any damages relating to your use of the information provided herein.
Please consult your broker or financial representative to verify pricing before executing any trade. Whyinvestin cannot guarantee the accuracy of the exchange rates used in the videos. You should confirm current rates before making any transactions that could be affected by changes in the exchange rates.
You agree not to copy, modify, reformat, download, store, reproduce, reprocess, transmit or redistribute any data or information found herein or use any such data or information in a commercial enterprise without obtaining prior written consent. Please consult your broker or financial representative to verify pricing before executing any trade.
COPYRIGHT “FAIR USE” Whyinvestin doesn’t own any logo different from the whyinvestin’ s logo contained in the video.
The owner of the logos is the subject of the video itself (the company); and all the logos are not authorized by, sponsored by, or associated with the trademark owner .
Whyinvestin uses exclusive rights held by the copyright owner for Educational purposes and for commentary and criticism as part of a news report or published article.
If you are a company, subject of the video and for any reason want to get in contact with Whyinvestin please email:
company@whyinvestin.com
- published: 16 Feb 2015
- views: 303
Visiting Celgene
- Order: Reorder
- Duration: 3:42
- Updated: 16 Nov 2015
- views: 586
What's up guys! I've had the most amazing few days visiting Celgene and learning about the future of cellular biology and how it will play into food manufacturi...
What's up guys! I've had the most amazing few days visiting Celgene and learning about the future of cellular biology and how it will play into food manufacturing.
These guys are the real deal. They're asking the questions nobody else is asking. But more importantly, they're answering questions no one else can answer. It is an incredible honor to be part of a brain trust of this caliber. Just being around this kind of high-level thinking is inspiring. Remember, you're the average of the 5 people you spend the most time with, so choose wisely.
Check out our website: www.insidequest.com
Follow me on Instagram: https://www.instagram.com/tombilyeu/
wn.com/Visiting Celgene
What's up guys! I've had the most amazing few days visiting Celgene and learning about the future of cellular biology and how it will play into food manufacturing.
These guys are the real deal. They're asking the questions nobody else is asking. But more importantly, they're answering questions no one else can answer. It is an incredible honor to be part of a brain trust of this caliber. Just being around this kind of high-level thinking is inspiring. Remember, you're the average of the 5 people you spend the most time with, so choose wisely.
Check out our website: www.insidequest.com
Follow me on Instagram: https://www.instagram.com/tombilyeu/
- published: 16 Nov 2015
- views: 586
Entrevista a Marta Moreno, de Celgene
- Order: Reorder
- Duration: 17:28
- Updated: 07 Nov 2015
- views: 82
Entrevista completa de Redacción Médica a Marta Moreno, Senior Director, Government Affairs & Market Access de Celgene.
Entrevista completa de Redacción Médica a Marta Moreno, Senior Director, Government Affairs & Market Access de Celgene.
wn.com/Entrevista A Marta Moreno, De Celgene
Entrevista completa de Redacción Médica a Marta Moreno, Senior Director, Government Affairs & Market Access de Celgene.
- published: 07 Nov 2015
- views: 82
Fireside Chat With Robert Hugin, Chairman and Chief Executive Officer, Celgene Corporation
- Order: Reorder
- Duration: 49:06
- Updated: 27 Feb 2013
- views: 1757
From the 15th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York on February 11th, 2013.
Robert Hugin
Chairman and Chief Executive O...
From the 15th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York on February 11th, 2013.
Robert Hugin
Chairman and Chief Executive Officer, Celgene Corporation
Mr. Hugin serves as Chairman and Chief Executive Officer of Celgene Corporation, a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for unmet medical needs in cancer and immune-inflammatory disease.
He joined Celgene in June 1999 and has been a Director of Celgene since December 2001. Mr. Hugin also serves as a Director of The Medicines Company, Atlantic Health System, Inc. and of Family Promise, a national non-profit network assisting homeless families. He serves as Chairman-Elect of The Pharmaceutical Research and Manufacturers of America and is a member of the Board of Trustees of The Darden Foundation, University of Virginia. He also serves on the Board of Trustees of Princeton University as well as a founding Board member of Choose NJ.
Prior to joining Celgene, Mr. Hugin was a Managing Director with J.P. Morgan & Co. Inc. Mr. Hugin received an AB degree from Princeton University in 1976 and an MBA from the University of Virginia in 1985 and served as a United States Marine Corps infantry officer during the intervening period. Bob and his wife Kathy have three children and live in Summit, New Jersey.
wn.com/Fireside Chat With Robert Hugin, Chairman And Chief Executive Officer, Celgene Corporation
From the 15th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York on February 11th, 2013.
Robert Hugin
Chairman and Chief Executive Officer, Celgene Corporation
Mr. Hugin serves as Chairman and Chief Executive Officer of Celgene Corporation, a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for unmet medical needs in cancer and immune-inflammatory disease.
He joined Celgene in June 1999 and has been a Director of Celgene since December 2001. Mr. Hugin also serves as a Director of The Medicines Company, Atlantic Health System, Inc. and of Family Promise, a national non-profit network assisting homeless families. He serves as Chairman-Elect of The Pharmaceutical Research and Manufacturers of America and is a member of the Board of Trustees of The Darden Foundation, University of Virginia. He also serves on the Board of Trustees of Princeton University as well as a founding Board member of Choose NJ.
Prior to joining Celgene, Mr. Hugin was a Managing Director with J.P. Morgan & Co. Inc. Mr. Hugin received an AB degree from Princeton University in 1976 and an MBA from the University of Virginia in 1985 and served as a United States Marine Corps infantry officer during the intervening period. Bob and his wife Kathy have three children and live in Summit, New Jersey.
- published: 27 Feb 2013
- views: 1757
Hugin Sees Celgene Revlimid Patents Holding Until 2027
- Order: Reorder
- Duration: 5:00
- Updated: 23 Mar 2012
- views: 780
Oct. 28 (Bloomberg) -- Robert Hugin, chief executive officer of Celgene Corp., talks about possible generic competition for Celgene's best-selling Revlimid canc...
Oct. 28 (Bloomberg) -- Robert Hugin, chief executive officer of Celgene Corp., talks about possible generic competition for Celgene's best-selling Revlimid cancer pill.
Hugin also discusses Celgene's drug pipeline and the acquisition of Abraxis BioScience Inc. He talks with Carol Massar and Matt Miller on Bloomberg Television's "Street Smart." (Source: Bloomberg)
wn.com/Hugin Sees Celgene Revlimid Patents Holding Until 2027
Oct. 28 (Bloomberg) -- Robert Hugin, chief executive officer of Celgene Corp., talks about possible generic competition for Celgene's best-selling Revlimid cancer pill.
Hugin also discusses Celgene's drug pipeline and the acquisition of Abraxis BioScience Inc. He talks with Carol Massar and Matt Miller on Bloomberg Television's "Street Smart." (Source: Bloomberg)
- published: 23 Mar 2012
- views: 780
Digging into Deals: Why Celgene Joined Up With Juno Therapeutics In 2015
- Order: Reorder
- Duration: 6:01
- Updated: 08 Jan 2016
- views: 203
The best defense is a good offense. A closer look at Celgene and Juno’s 10-year developing and marketing agreement.
This podcast was recorded on Jan 6, 2016.
...
The best defense is a good offense. A closer look at Celgene and Juno’s 10-year developing and marketing agreement.
This podcast was recorded on Jan 6, 2016.
Imagine owning Amazon.com (up over an insane 4,000% since 2001) when Internet sales rendered big-box retailers obsolete... Now an industry 99% of us use daily is set to implode... And 3 established companies are positioned to take advantage. Click http://bit.ly/1zQXjzy for a stunning presentation.
------------------------------------------------------------------------
Subscribe to The Motley Fool's YouTube Channel:
http://www.youtube.com/TheMotleyFool
Or, follow our Google+ page:
https://plus.google.com/+MotleyFool/posts
Inside The Motley Fool: Check out our Culture Blog!
http://culture.fool.com
Join our Facebook community:
https://www.facebook.com/themotleyfool
Follow The Motley Fool on Twitter:
https://twitter.com/themotleyfool
wn.com/Digging Into Deals Why Celgene Joined Up With Juno Therapeutics In 2015
The best defense is a good offense. A closer look at Celgene and Juno’s 10-year developing and marketing agreement.
This podcast was recorded on Jan 6, 2016.
Imagine owning Amazon.com (up over an insane 4,000% since 2001) when Internet sales rendered big-box retailers obsolete... Now an industry 99% of us use daily is set to implode... And 3 established companies are positioned to take advantage. Click http://bit.ly/1zQXjzy for a stunning presentation.
------------------------------------------------------------------------
Subscribe to The Motley Fool's YouTube Channel:
http://www.youtube.com/TheMotleyFool
Or, follow our Google+ page:
https://plus.google.com/+MotleyFool/posts
Inside The Motley Fool: Check out our Culture Blog!
http://culture.fool.com
Join our Facebook community:
https://www.facebook.com/themotleyfool
Follow The Motley Fool on Twitter:
https://twitter.com/themotleyfool
- published: 08 Jan 2016
- views: 203
Next Big Thing in Biotech: Celgene
- Order: Reorder
- Duration: 2:20
- Updated: 13 Jan 2012
- views: 2476
Next Big Thing in Biotech: Celgene
Next Big Thing in Biotech: Celgene
wn.com/Next Big Thing In Biotech Celgene
Cramer: Why Celgene Makes Sense
- Order: Reorder
- Duration: 2:16
- Updated: 21 Mar 2012
- views: 838
Mad Money Uncovered: Biogen and Celgene, Biotech innovators
- Order: Reorder
- Duration: 3:08
- Updated: 27 Mar 2013
- views: 1199
Jim Cramer talks growth in the biotech space with Mad Money research director Nicole Urken
- published: 27 Mar 2013
- views: 1199
(CELG) Celgene Corporation
- Order: Reorder
- Duration: 7:47
- Updated: 31 Dec 2014
- views: 143
Nair apprenti informaticien chez Celgene
- Order: Reorder
- Duration: 3:01
- Updated: 02 Feb 2016
- views: 16
Emission du 18.07.2013
Il n'est pas tombé dedans quand il était petit! Nair a découvert l'informatique chez son cousin, mais de là à en faire son métier! Et po...
Emission du 18.07.2013
Il n'est pas tombé dedans quand il était petit! Nair a découvert l'informatique chez son cousin, mais de là à en faire son métier! Et pourtant, il s'est lancé dans le domaine, sans stages préalables et ça a été une révélation. Comble de chance, il a décroché sa place dans la prestigieuse entreprise internationale Celgene à Boudry.
A voir aussi sur :
http://monjobetmoi.ch
http://www.canalalpha.ch/emissions/monjobetmoi/
wn.com/Nair Apprenti Informaticien Chez Celgene
Emission du 18.07.2013
Il n'est pas tombé dedans quand il était petit! Nair a découvert l'informatique chez son cousin, mais de là à en faire son métier! Et pourtant, il s'est lancé dans le domaine, sans stages préalables et ça a été une révélation. Comble de chance, il a décroché sa place dans la prestigieuse entreprise internationale Celgene à Boudry.
A voir aussi sur :
http://monjobetmoi.ch
http://www.canalalpha.ch/emissions/monjobetmoi/
- published: 02 Feb 2016
- views: 16
close fullscreen
- Playlist
- Chat
close fullscreen
- Playlist
- Chat
69:53
Robert J. Hugin, Chairman & CEO of Celgene Corporation
Robert J. Hugin (MBA '85), a member of the Darden School Foundation Board of Trustees, and...
published: 11 Sep 2014
Robert J. Hugin, Chairman & CEO of Celgene Corporation
Robert J. Hugin, Chairman & CEO of Celgene Corporation
- Report rights infringement
- published: 11 Sep 2014
- views: 2400
2:09
Celgene Corp - Why Invest in
VIDEO FINANCIAL REPORTING
Why invest in is the first financial video platform where you c...
published: 16 Feb 2015
Celgene Corp - Why Invest in
Celgene Corp - Why Invest in
- Report rights infringement
- published: 16 Feb 2015
- views: 303
3:42
Visiting Celgene
What's up guys! I've had the most amazing few days visiting Celgene and learning about the...
published: 16 Nov 2015
Visiting Celgene
Visiting Celgene
- Report rights infringement
- published: 16 Nov 2015
- views: 586
17:28
Entrevista a Marta Moreno, de Celgene
Entrevista completa de Redacción Médica a Marta Moreno, Senior Director, Government Affair...
published: 07 Nov 2015
Entrevista a Marta Moreno, de Celgene
Entrevista a Marta Moreno, de Celgene
- Report rights infringement
- published: 07 Nov 2015
- views: 82
49:06
Fireside Chat With Robert Hugin, Chairman and Chief Executive Officer, Celgene Corporation
From the 15th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New Yor...
published: 27 Feb 2013
Fireside Chat With Robert Hugin, Chairman and Chief Executive Officer, Celgene Corporation
Fireside Chat With Robert Hugin, Chairman and Chief Executive Officer, Celgene Corporation
- Report rights infringement
- published: 27 Feb 2013
- views: 1757
5:00
Hugin Sees Celgene Revlimid Patents Holding Until 2027
Oct. 28 (Bloomberg) -- Robert Hugin, chief executive officer of Celgene Corp., talks about...
published: 23 Mar 2012
Hugin Sees Celgene Revlimid Patents Holding Until 2027
Hugin Sees Celgene Revlimid Patents Holding Until 2027
- Report rights infringement
- published: 23 Mar 2012
- views: 780
6:01
Digging into Deals: Why Celgene Joined Up With Juno Therapeutics In 2015
The best defense is a good offense. A closer look at Celgene and Juno’s 10-year developing...
published: 08 Jan 2016
Digging into Deals: Why Celgene Joined Up With Juno Therapeutics In 2015
Digging into Deals: Why Celgene Joined Up With Juno Therapeutics In 2015
- Report rights infringement
- published: 08 Jan 2016
- views: 203
2:20
Next Big Thing in Biotech: Celgene
Next Big Thing in Biotech: Celgene
published: 13 Jan 2012
Next Big Thing in Biotech: Celgene
Next Big Thing in Biotech: Celgene
- Report rights infringement
- published: 13 Jan 2012
- views: 2476
2:16
Cramer: Why Celgene Makes Sense
Cramer: Why Celgene Makes Sense
published: 21 Mar 2012
Cramer: Why Celgene Makes Sense
Cramer: Why Celgene Makes Sense
- Report rights infringement
- published: 21 Mar 2012
- views: 838
3:08
Mad Money Uncovered: Biogen and Celgene, Biotech innovators
Jim Cramer talks growth in the biotech space with Mad Money research director Nicole Urken...
published: 27 Mar 2013
Mad Money Uncovered: Biogen and Celgene, Biotech innovators
Mad Money Uncovered: Biogen and Celgene, Biotech innovators
- Report rights infringement
- published: 27 Mar 2013
- views: 1199
7:47
(CELG) Celgene Corporation
(CELG) Celgene Corporation
published: 31 Dec 2014
(CELG) Celgene Corporation
(CELG) Celgene Corporation
- Report rights infringement
- published: 31 Dec 2014
- views: 143
3:01
Nair apprenti informaticien chez Celgene
Emission du 18.07.2013
Il n'est pas tombé dedans quand il était petit! Nair a découvert l...
published: 02 Feb 2016
Nair apprenti informaticien chez Celgene
Nair apprenti informaticien chez Celgene
- Report rights infringement
- published: 02 Feb 2016
- views: 16
Robert J. Hugin, Chairman & CEO of Celgene Corpora...
Celgene Corp - Why Invest in...
Visiting Celgene...
Entrevista a Marta Moreno, de Celgene...
Fireside Chat With Robert Hugin, Chairman and Chie...
Hugin Sees Celgene Revlimid Patents Holding Until ...
Digging into Deals: Why Celgene Joined Up With Jun...
Next Big Thing in Biotech: Celgene...
Cramer: Why Celgene Makes Sense...
Mad Money Uncovered: Biogen and Celgene, Biotech i...
(CELG) Celgene Corporation...
Nair apprenti informaticien chez Celgene...
-
Lyrics list:lyrics
-
Sloe Gin
Sloe Gin
Sloe Gin, sloe Gin
Tryin' to wash away the pain inside
Well I'm sick and I'm all done in
And I'm standing in the rain
And I feel like I'm gonna cry
I'm so damn lonely
And I ain't even high
I'm so damn lonely
And I feel like I'm gonna die
Mayday, mayday I've been shot down
Over the stormy sea
Well I feel that I'm drifting away
Can not seem to get a grip on me
Well. I can't even try
I'm so damn lonely
Ain't even high
I hate to go home alone,
But what else is new?
I'm so damn lonely
I hate to go home alone,
But what else is new?
I'm so damn lonely…
You stand and bleeding people pass me by
No matter if you live
No matter if you die
Sloe Gin, sloe Gin
Tryin' to wash away the pain inside
Well I'm sick and I'm all done in
I'm standing in the rain
And I feel like I'm gonna cry
I'm so damn lonely
Ain't even high
photo: AP / Bullit Marquez
Unofficial Vote Count Shows Rodrigo Duterte Has Won Presidential Election in the Philippines
Edit Time Magazine 09 May 2016
Rodrigo Duterte, the controversial mayor of Davao City, appeared to win the presidential election in the Philippines on Monday night, besting four challengers despite a campaign marred by rape jokes, death threats and various obscenities ... Under Philippine election law, the candidate with the most votes wins even without a clear majority. As of 1 a.m ... Duterte insists his forces only use deadly force when encountering violent resistance....
photo: AP / Alexander Zemlianichenko
Russian President Ranks Sixth In World's Most Admired Poll
Edit WorldNews.com 09 May 2016
Russian President Vladimir Putin is apparently well admired in his country, but a poll shows he is also respected beyond the boundaries of his own nation, Newsweek reports.Although the Kremlin’s violent foreign policy is noteworthy, Putin ranks as the sixth most-admired man in the world in an annual survey by pollster YouGov – that’s five places higher compared to his 2015 result ... Globally, U.S ... Former U.S ... U.S....
photo: Public Domain / Ukrainian SSR
The Soviet Union helped save the world from Hitler during World War II
Edit The Independent 09 May 2016
In the Western popular imagination -- particularly the American one -- World War II is a conflict we won. It was fought on the beaches of Normandy and Iwo Jima, through the rubble of recaptured French towns and capped by sepia-toned scenes of joy and young love in New York. It was a victory shaped by the steeliness of Gen. Dwight D ... It's a grand moment, but few of the world's major leaders will be in attendance ... Copyright....
photo: Via YouTube
![Police Arrest 13 For Burning A Girl Who Helped A Couple Elope [Video]](http://web.archive.org./web/20160510080228im_/http://cdn6.wn.com/ph/img/5e/cc/66a80ca4b145ea6ed6a3ace3a776-medium.jpg "Police Arrest 13 For Burning A Girl Who Helped A Couple Elope [Video]")
Police Arrest 13 For Burning A Girl Who Helped A Couple Elope [Video]
Edit Inquisitr 09 May 2016
Pakistani Police have arrested 13 people suspected of burning a girl alive. The arrest was made on Thursday last week. The people arrested belonged to a tribal council in Pakistan. The girl was left unconscious after being drugged. She was kept in a van which was set in fire outside Islamabad ... Replug. In Pakistani village, there is anger, but mostly shock, after the brutal "honour killing" of 16-yr-old girl https.//t.co/8vx9QBpDSN....
photo: AP / Mel Evans
Trump, Sanders And Political Psychology Of “Momentum”
Edit WorldNews.com 09 May 2016
Article by WN.com Correspondent Dallas Darling. Believe it or not, our brains are hard-wired to take ideas such as momentum and trajectory and apply them to political and social events that have nothing to do with physical movement ... Likewise, and on the heels of winning a resounding majority of the last 15 state primaries, Democratic candidate Sen. Bernie Sanders won Indiana, unexpectedly surprising former U.S ... Meanwhile, from Feb ... 40.....
« back to news headlines
Mesoblast boss' losses mount on research, funding concerns
Edit Sydney Morning Herald 10 May 2016
But it was the company's defensive response to analyst questioning on Tuesday that prompted quick selling, with doubts over the status of a deal with US biotech major Celgene and over the backing of Teva Pharmaceutical for a heart failure research program ... It was only after relentless questioning [Mesoblast] admitted the right of first refusal with Celgene is no longer there....
Juno Therapeutics Reports First Quarter 2016 Financial Results (Juno Therapeutics Inc)
Edit Public Technologies 09 May 2016
-- In April, Celgene exercised opt-in right for the CD19 program -- ... 'In the first quarter, we continued to advance our CD19-directed portfolio - enrolling multiple trials, commencing manufacturing of clinical trial material from our Juno-operated facility, and securing Celgene's opt-in to product candidates in our CD19 program, which will accelerate our pace outside of North America....
IMMUNOVIA JOINS MORE THAN 40 GLOBAL PANCREATIC CANCER ORGANIZATIONS AT INAGURAL MEETING (Immunovia AB)
Edit Public Technologies 09 May 2016
(Source ... Three years ago, in 2013, pancreatic cancer patient advocacy organizations from around the world, with founding sponsor Celgene Corporation, began discussions about how best to support each other's efforts while raising global awareness for the deadly disease ... 17 ... The World Pancreatic Cancer Coalition has the generous support of corporate sponsors Celgene Corporation, Baxalta Incorporatedand Halozyme Therapeutics ... Mats Grahn....
bluebird bio Presents Oncology and Gene Therapy Data at the ASGCT 19th Annual Meeting (Bluebird Bio Inc)
Edit Public Technologies 09 May 2016
bluebird bio's lead oncology program, bb2121, is an anti-BCMA CAR T program partnered with Celgene ... of patients in our clinical studies, the risk that our collaboration with Celgene will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed and commercialized....
Drug Stocks Reporting on May 10: XON, ARIA, CPRX & More
Edit Yahoo Daily News 09 May 2016
Moreover, this trend of earnings declines is expected to continue into the second quarter as well ... The earnings picture for both the pharma and the biotech sector looks pretty mixed with beats and misses. While in the biotech sector, Amgen Inc ... Among the other biotech stocks, Biogen, Celgene, Alexion and AbbVie managed to post mixed results, while some others came up with disappointing results and outlook for the year ... Jazz Q1 Earnings ... ....
Epizyme Announces First Quarter 2016 Financial Results and Provides Update on Execution Against Multi-Year Company Vision
Edit Stockhouse 09 May 2016
In addition, discovery and preclinical research costs are expected to increase as the Company advances its wholly owned small molecule programs against five novel targets and continues the research efforts under its Celgene collaboration....
Epizyme Announces First Quarter 2016 Financial Results and Provides Update on Execution Against Multi-Year Company Vision (Epizyme Inc)
Edit Public Technologies 09 May 2016
In addition, discovery and preclinical research costs are expected to increase as the Company advances its wholly owned small molecule programs against five novel targets and continues the research efforts under its Celgene collaboration....
S&P; 500 closes flat as metals offset health-care sector rally
Edit Sydney Morning Herald 09 May 2016
The S&P 500 closed little changed as a rally in health-care shares was offset by declines among commodity producers, while investors awaited a final batch of earnings reports and further clues on prospects for the economy. Health-care stocks jumped after their worst two weeks since February, while energy producers slid for a second day amid lower crude prices ... Celgene and Biogen each added at least 2.1 per cent ... ....
Celgene Corp, Novartis, Sanofi - Research and Markets
Edit Business Wire 06 May 2016
DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Myelodysplastic Syndrome Global Clinical Trials Review, H1, 2016" clinical trials to their offering. The clinical trial report, Myelodysplastic Syndrome Global Clinical Trials Review, H1, 2016" provides an overview of Myelodysplastic Syndrome clinical trials scenario ... Report includes an overview of trial numbers and thei ... ....
Gilead New CEO Says It's Time to Go Out and Do Important Deals
Edit Bloomberg 06 May 2016
John Milligan was the 32nd employee at Gilead Sciences Inc. when he was hired as a research scientist in 1990. Now, he’s at the helm of the biggest biotechnology firm in the world, charged with maintaining the company’s blistering pace of growth to satisfy investors anxious about a slowdown in its blockbuster hepatitis C treatments ... “We need some other assets that can bolster our pipeline.” ... The market is crowded. Celgene Inc ... ....
Celgene CEO Mark Alles Headlines NewYorkBIO Annual Conference, May 11-12
Edit Business Wire 05 May 2016
NEW YORK--(BUSINESS WIRE)--$celg #biotech--Mark Alles, CEO of Celgene, will headline the NewYorkBIO Annual Conference, May 11-12 in New York City ... ....
Acceleron Pharma Reports First Quarter 2016 Financial and Operational Results (Acceleron Pharma Inc)
Edit Public Technologies 05 May 2016
- Received $15 million milestone payment for Celgene's initiation of luspatercept Phase 3 clinical trial - ... 'In the first quarter, we continued to build momentum across our entire clinical pipeline, including the start of patient recruitment into our Phase 3 trials of luspatercept in MDS and beta-thalassemia with our partner Celgene,' said John Knopf, Ph.D., Chief Executive Officer of Acceleron....
- 1
- 2
- 3
- 4
- 5
- Next page »
